Experimental Treatment Earns Breakthrough Therapy Designation for TK2 Deficiency, a Form of Mitochondrial Disease
According to a story from BioSpace, the biopharmaceutical company Modis Therapeutics recently announced that the US Food and Drug Administration (FDA) has granted Breakthough Therapy designation for the company's experimental…